ARYBALLE TECHNOLOGIES

Their core work

Aryballe Technologies is a French deep-tech SME that develops digital olfaction technology — sensors and systems that digitize the sense of smell. Their core hardware expertise centers on bio-inspired olfactory sensor arrays, including CMUT (Capacitive Micromachined Ultrasonic Transducer)-based devices capable of detecting and identifying volatile chemical compounds with precision. In the Rose project (2021-2025), they are applying this technology to a medically significant problem: building sensor and stimulation systems to help patients with olfactory deficits regain smell recognition. They sit at the intersection of MEMS sensor engineering, olfactory neuroscience, and biomedical device development.

What they specialise in

How they've shifted over time

Aryballe entered H2020 through the CHESS project (2015-2019), an MSCA-ITN training network for connected health researchers, where they participated as an industry third party — a role typical of startups contributing specialized technology know-how to academic PhD programs without taking on formal coordination. By the Rose project (2021-2025), their profile had sharpened dramatically: CMUT sensors, digital olfaction, human olfaction science, and olfactory stimulation arrays are all specific, committed technical areas rather than broad positioning. The shift from a generic "connected health" ecosystem role to targeted olfactory rehabilitation technology suggests a company that has found and is doubling down on a defensible medical-sensor niche.

Aryballe is converging on the medical application of digital olfaction — specifically assistive and diagnostic devices for smell disorders — signaling a strategic commitment to health sensing as their primary commercial vertical.

How they like to work

Aryballe has not led any H2020 project as coordinator, consistently joining as a specialist participant or third-party contributor who brings proprietary sensor hardware rather than project management capacity. Their footprint across 22 partners in 10 countries — from just 2 projects — shows they are comfortable in large, internationally distributed consortia typical of FET and MSCA programs. This pattern of deep-technology contribution without coordination responsibility is characteristic of focused deep-tech SMEs that prioritize protecting and advancing their core IP rather than managing multi-partner logistics.

Through 2 projects, Aryballe has engaged with 22 unique consortium partners across 10 countries, reflecting involvement in large pan-European research consortia. No strong geographic clustering is apparent from the available data.

What sets them apart

Aryballe occupies an extremely narrow but commercially valuable niche: they are among the very few European SMEs with commercial-grade digital olfaction hardware, bridging MEMS fabrication, olfactory neuroscience, and medical device development in a single company. For consortium builders, this means a partner who can deliver working sensor prototypes rather than purely academic outputs — a rare asset in any health-tech or sensing-technology consortium. In the context of smell rehabilitation, food quality, or environmental sensing, they bring something most research institutions simply cannot: a product-grade technology pipeline grounded in proprietary sensor design.

Highlights from their portfolio

• Rose
  Aryballe's most technically specific H2020 engagement, applying CMUT sensor and digital olfaction expertise directly to a biomedical challenge — restoring odorant recognition in smell-impaired patients — with EUR 364,761 in EC funding as a full participant.
• CHESS
  An early MSCA training network that embedded Aryballe in the connected health research community as an industry mentor, establishing the company's academic partnerships before their medical olfaction focus crystallized.